Lupus erythematosus and other autoimmune diseases related to statin therapy: A systematic review

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 1, 2007, Pages 17-24

  Noël, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Autoimmune diseases; Dermatomyositis; Lupus erythematosus; Polymyositis; Statin

Indexed keywords

ANTINUCLEAR ANTIBODY; ATORVASTATIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUINDOSTATIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MEVINOLIN; PRAVASTATIN; PREDNISONE; SIMVASTATIN; TACROLIMUS;

AUTOIMMUNE DISEASE; DERMATOMYOSITIS; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; LICHEN PLANUS; LUPUS ERYTHEMATOSUS; MEDICAL LITERATURE; MEDLINE; ONSET AGE; PEMPHIGOID; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 33845629866     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01838.x     Document Type: Review

References (59)

1. Noël B. Autoimmune disease and other potential side-effects of statins. Lancet 2004; 363: 2000.
2. Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991; 151: 1667-1668.
3. Bannwarth B, Miremont G, Papapietro PM. Lupus-like syndrome associated with simvastatin. Arch Intern Med 1992; 152: 1093.
4. Hanson J, Bossingham D. Lupus-like syndrome associated with simvastatin. Lancet 1998; 352: 1070.
5. Rudski L, Rabinovitch MA, Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature. Medicine (Baltimore) 1998; 77: 378-383.
6. Khosla R, Butman AN, Hammer DF. Simvastatin-induced lupus erythematosus. South Med J 1998; 91: 873-874.
7. Sridhar MK, Abdulla A. Fatal lupus-like syndrome and ARDS induced by fluvastatin. Lancet 1998; 352: 114.
8. Ahmad A, Fletcher MT, Roy TM. Simvastatin-induced lupus-like syndrome. Tenn Med 2000; 93: 21-22.
9. Jimenez-Alonso J, Jaimez L, Sabio JM, Hidalgo C, Leon L. Atorvastatin-induced reversible positive antinuclear antibodies. Am J Med 2002; 112: 329-330.
10. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003; 12: 409-412.
11. Srivastava M, Rencic A, Diglio G et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139: 45-49.
12. Noël B, Panizzon RG. Lupus-like syndrome associated with statin therapy. Dermatology 2004; 208: 276-277.
13. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992; 327: 649-650.
14. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994; 33: 199.
15. Rodriguez-Garcia JL, Serrano CM. Lovastatin-associated dermatomyositis. Postgrad Med J 1996; 72: 694.
16. Noël B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med 2001; 110: 670-671.
17. Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, Toribio E. Severe polymyositis with simvastatin use [in Spanish]. Rev Neurol 2003; 37: 934-936.
18. Fauchais AL, Iba Ba J, Maurage P et al. Polymyosites induites ou associées aux traitements hypolipémiants? A propos de cinq cas. Rev Med Interne 2004; 25: 294-298.
19. Takagi A, Shiio Y. [Pravastatin-associated polymyositis, a case report]. Rinsho Shinkeigaku 2004; 44: 25-27.
20. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995; 25: 745-746.
21. Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004.
22. Zuech P, Pauwels C, Duthoit C et al. [Pravastatin-induced dermatomyositis]. Rev Med Interne 2005.
23. Thual N, Penven K, Chevallier J, Dompmartin A, Leroy D. Dermatomyosite induite par la fluvastatine. Ann Dermatol Venereol 2004; 131: S212.
24. Stoebner PE, Michot C, Ligeron C et al. [Simvastatin-induced lichen planus pemphigoides]. Ann Dermatol Venereol 2003; 130: 187-190.
25. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004; 147: 956-965.
26. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004; 363: 892-894.
27. Phillips PS, Haas RH, Bannykh S et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-585.
28. Mevorach D. Systemic lupus erythematosus and apoptosis: A question of balance. Clin Rev Allergy Immunol 2003; 25: 49-60.
29. Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001; 144: 958-966.
30. Blanco-Colio LM, Villa A, Ortego M et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002; 161: 17-26.
31. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003; 31: 779-783.
32. Rovere P, Sabbadini MG, Fazzini F et al. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 2000; 43: 1663-1672.
33. Millard TP, Hawk JL, McGregor JM. Photosensitivity in lupus. Lupus 2000; 9: 3-10.
34. Caricchio R, McPhie L, Cohen PL. Ultraviolet B radiation-induced cell death: Critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol 2003; 171: 5778-5786.
35. Pablos JL, Santiago B, Galindo M et al. Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. J Pathol 1999; 188: 63-68.
36. Quiec D, Maziere C, Auclair M et al. Lovastatin enhances the photocytotoxicity of UVA radiation towards cultured N.C.T.C. 2544 human keratinocytes: Prevention by cholesterol supplementation and by a cathepsin inhibitor. Biochem J 1995; 310: 305-309.
37. Holme SA, Pearse AD, Anstey AV. Chronic actinic dermatitis secondary to simvastatin. Photodermatol Photoimmunol Photomed 2002; 18: 313-314.
38. Morimoto K, Kawada A, Hiruma M, Ishibashi A, Banba H. Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. Contact Dermatitis 1995; 33: 274.
39. Frost P, Weinstein GD, Gomez EC. Phototoxic potential of minocycline and doxycycline. Arch Dermatol 1972; 105: 681-683.
40. Smilack JD. The tetracyclines. Mayo Clin Proc 1999; 74: 727-729.
41. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692.
42. Fehr T, Kahlert C, Fierz W et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004; 175: 83-90.
43. Ehrenstein MR, Jury EC, Mauri C. Statins for atherosclerosis - as good as it gets? N Engl J Med 2005; 352: 73-75.
44. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481-490.
45. Palinski W. Immunomodulation: A new role for statins? Nat Med 2000; 6: 1311-1312.
46. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402.
47. Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
48. Hakamada-Taguchi R, Uehara Y, Kuribayashi K et al. Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-956.
49. Steinman L. Immune therapy for autoimmune diseases. Science 2004; 305: 212-216.
50. Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 2005; 15: 202-206.
51. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004; 172: 2903-2908.
52. Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608.
53. McCarey DW, McInnes PI, Madhok R et al. Trial of atorvastatin in rheumatoid arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015-2021.
54. Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 2004; 18: 677-688.
55. Vial T, Nicolas B, Descotes J. Drug-induced autoimmunity: Experience of the French pharmacovigilance system. Toxicology 1997; 119: 23-27.
56. Gotto AM Jr. Lipid management in patients at moderate risk for coronary heart disease: Insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Med 1999; 107: 36S-39S.
57. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH et al. Undertreatment of hypercholesterolaemia: A population-based study. Br J Clin Pharmacol 2003; 55: 389-397.
58. Choudhry NK, Avorn J. Over-the-counter statins. Ann Intern Med 2005; 142: 910-913.
59. Link M. Statin switch to OTC. Nat Rev Drug Discov 2004; 3: 641-642.